SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

March 01, 2011 18:00 ET

SciClone Pharmaceuticals to Present at Two Investor Conferences in March

Cowen Healthcare Conference on Monday, March 7 at 1:00 pm ET; Rodman & Renshaw Annual China Investment Conference on Tuesday, March 8 at 2:00 pm Shanghai time

FOSTER CITY, CA--(Marketwire - March 1, 2011) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: Cowen Healthcare Conference and Rodman & Renshaw Annual China Investment Conference. SciClone's executives will present a corporate overview and business update at each conference.

WHEN:
Cowen Healthcare Conference
Monday, March 7 at 1:00 pm ET
Boston, MA
Presenter: Gary Titus, Senior Vice President and CFO

WHEN:
Rodman & Renshaw Annual China Investment Conference
Tuesday, March 8 at 2:00 pm Shanghai time
Shanghai, China
Presenter: Friedhelm Blobel, Ph.D., President and CEO

To access the live audio webcasts of the Rodman & Renshaw presentation, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com. At the Cowen conference, SciClone is presenting on a panel that is not being webcast by the conference organizers.

About SciClone
SciClone Pharmaceuticals (NASDAQ: SCLN) is a revenue-generating, China-centric, specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. The Company is focused on continuing sales growth and executing a clinical development strategy with prudently managed costs. ZADAXIN® (thymalfasin) is approved in over 30 countries for the treatment of hepatitis B (HBV), as a vaccine adjuvant, for the treatment of hepatitis C (HCV), and certain cancers. SciClone is evaluating SCV-07 in a phase 2b trial to modify the course of oral mucositis in patients with head and neck cancer. The Company also has exclusive commercialization and distribution rights in China to a novel treatment for advanced liver cancer, DC Bead®, which is already approved in approximately 40 countries worldwide, including the U.S. and several countries in Europe. DC Bead is currently under review by regulatory agencies in China. Additionally, SciClone owns exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm® in China, including Hong Kong and Macau, and Vietnam. The Company intends to seek regulatory approval for the product, commonly used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery, in these markets. For additional information, please visit www.sciclone.com.

DC Bead is a registered trademark of Biocompatibles UK Limited.

RapidFilm is a registered trademark of Labtec Gesellschaft für technologische Forschung und Entwicklung mbH.